Upregulation of the anti-apoptotic protein B-Cell Lymphoma 2 (BCL-2), observed to increase with Gleason grade, a system used to evaluate the aggressiveness of prostate cancer based on microscopic appearance, and disease progression, confers a significant survival advantage to tumor cells and is a key mechanism for acquiring resistance to androgen-targeted therapies [7]. This evidence concerns the gene BCL2 and prostate cancer.